Predicting Epilepsy Treatment Success with Implanted Devices
Implanted Device Shows Promise in Predicting Epilepsy Treatment Success
WATCH TIME: 6 minutes
“This is just the beginning. With [responsive neurostimulation] and other upcoming implanted devices, we’re entering an era of even more advanced seizure detection and prediction.”
A groundbreaking study presented at the 2024 American Epilepsy Society Annual meeting in Los Angeles offers hope for more effective epilepsy treatment. Researchers investigated the potential of implanted devices to predict how well a new anti-seizure medication (ASM) will work for individual patients.
The study focused on the RNS System, an implanted device that detects and responds to abnormal brain activity associated with seizures. Analyzing data from 45 patients, researchers found a strong correlation between reductions in “long episodes” (LE) – periods of abnormal brain activity detected by the RNS System – and reductions in clinical seizures.
Patients who experienced at least a 30% reduction in LE frequency were substantially more likely to see at least a 50% reduction in clinical seizures, with a 70% success rate. These findings suggest that LE frequency could serve as a reliable biomarker, allowing doctors to predict the effectiveness of new ASMs earlier in the growth process.”These results are incredibly encouraging,” said Dr. Jacqueline A. French, a professor of neurology at NYU Grossman School of Medicine and co-author of the study. “They demonstrate the potential of implanted devices like the RNS System to not only treat seizures but also to guide treatment decisions and improve patient outcomes.”
Dr.French believes this technology could revolutionize epilepsy management.
“We’re moving towards a future where we can personalize treatment based on individual patient needs,” she explained. “Implanted devices will play a crucial role in this evolution, allowing us to predict treatment response and tailor therapies for optimal results.”
The studyS findings have notable implications for the development of new epilepsy treatments. By using data from implanted devices like the RNS system, researchers can more efficiently evaluate the effectiveness of novel therapies in the early stages of development. This could accelerate the process of bringing new and improved treatments to patients.
Click here for more AES 2024 coverage.
Implanted Device shows Promise in Predicting Epilepsy Treatment Success
Dr. Jacqueline A. French, a professor of neurology at NYU Grossman School of Medicine and co-author of a groundbreaking new study, discusses the potential of implanted devices to revolutionize epilepsy treatment.
NewsDirectory3: dr. French, your recent research presented at the 2024 American Epilepsy Society Annual Meeting focused on the use of implanted devices to predict the success of new anti-seizure medications (ASMs). can you elaborate on your findings?
Dr. French: Absolutely. Our study investigated the RNS System,an implanted device that detects and responds to abnormal brain activity associated with seizures. we analyzed data from 45 patients and found a strong correlation between reductions in “long episodes” (LE) – periods of abnormal brain activity detected by the RNS System – and reductions in clinical seizures. Patients who experienced at least a 30% reduction in LE frequency were substantially more likely to see at least a 50% reduction in clinical seizures,with a 70% success rate. This suggests that LE frequency could be a reliable biomarker, allowing doctors to predict the effectiveness of new ASMs earlier in the process.
NewsDirectory3: these findings are certainly promising. How could this technology change the way epilepsy is managed?
Dr. French: These results are incredibly encouraging. They demonstrate the potential of implanted devices like the RNS System to not only treat seizures but also guide treatment decisions and improve patient outcomes.
We’re moving towards a future where we can personalize treatment based on individual patient needs. Implanted devices will play a crucial role in this evolution, allowing us to predict treatment response and tailor therapies for optimal results.
NewsDirectory3: Could this technology also impact the development of new epilepsy treatments?
Dr. French: Absolutely. Using data from implanted devices like the RNS System, researchers can more efficiently evaluate the effectiveness of novel therapies in the early stages of development. This could accelerate the process of bringing new and improved treatments to patients.
NewsDirectory3: This is truly groundbreaking research. Thank you for sharing your insights, Dr. French.